Fundz
Back to SEC Filings
10-KMEDIUM RiskDETERIORATING

ADAPTIN BIO, INC.

adaptinbio.com
Filed: Apr 1, 2026 CIK: 0001938571Health Care
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-K filing content

Adaptin Bio is a high-risk biotechnology company facing severe financial distress with going concern issues and substantial capital requirements. The company shows no revenue generation and appears to be entirely dependent on external funding for survival, with significant regulatory and operational uncertainties surrounding their drug development pipeline.

Red Flags Detected (7)

Going concern qualification - substantial doubt about ability to continue operations

No revenue generation from operations

Heavy reliance on external funding with uncertain capital raising ability

4 more red flags detected

Key Takeaways

Company is pre-revenue with no established income stream

Survival entirely dependent on successful capital raises

3 more takeaways

Filing Overview

Form TypeAnnual Report (10-K)
Filing DateApr 1, 2026
Risk LevelMEDIUM
TrendDETERIORATING
AI Confidence85%
Red Flags7

What This Means

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.

View Full Filing on SEC.govBrowse More Filings